"Company CFO John Smiley reported that the pharma giant is planning to clock $1 billion to $5 billion worth of deals for each quarter of 2020."

That's bad news for those who are pinning their hopes on a buyout. It looks like they can't afford us unless they stretch the acquisition across multiple quarters.